Search
Heme arginate
go.drugbank.com/drugs/DB17310InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds with 4 or More RingsPivekimab sunirine
go.drugbank.com/drugs/DB17337ApprovedInvestigationalSynonyms: HUMANISED IgG1 KAPPA ANTI-CD123 MONOCLONAL ANTIBODY G4723AB - SULFONATED DGN549-C CONJUGATE IMGN632, Indolino-benzodiazepine compound (sulfonated DGN549-C) conjugated to the humanized anti-CD123 monoclonal antibody (G4723A)MGN-4893
go.drugbank.com/drugs/DB17338ExperimentalMGN-4893 is an inhibitor of microRNA-451. In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.[L47356]
NC-6300
go.drugbank.com/drugs/DB17341ExperimentalNC-6300, also known as K-912, is a novel [epirubicin] drug-conjugated polymeric micelle.
Trimethyltetradecylammonium
go.drugbank.com/drugs/DB17342ExperimentalSynonyms: 1-tetradecanaminium, n,n,n-trimethyl-Categories: Compounds used in a research, industrial, or household settingOcaratuzumab
go.drugbank.com/drugs/DB17359InvestigationalOcaratuzumab is a humanized monoclonal antibody directed against CD20. It is being investigated for cancers and autoimmune disorders.
Synonyms: Immunoglobulin G1, anti-(human B-lymphocyte antigen CD20 (B-lymphocyte surface antigen B1, Bp35, leukocyte surface antigen Leu-16, membrane-spanning 4-domains subfamily A member 1))AMG-119
go.drugbank.com/drugs/DB17363InvestigationalAMG-119 are CAR-T cells targeting delta-like ligand 3 (DLL3).[A254811]
AUTO3
go.drugbank.com/drugs/DB17364InvestigationalIt is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22. … AUTO3 is bicistronic chimeric antigen receptor T-cell therapy investigated for acute lymphoblastic leukemia (ALL).
Synonyms: AUTO 3LioCyx-M004
go.drugbank.com/drugs/DB17368InvestigationalLioCyx-M004 are autologous T cells transduced with a retroviral vector encoding a hepatitis B virus antigen-specific T cell receptor.
Synonyms: mRNA HBV/TCR T-cellsTBX-3400
go.drugbank.com/drugs/DB17370InvestigationalTBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.